2.30
price up icon0.00%   0.00
pre-market  시장 영업 전:  2.46   0.16   +6.96%
loading
전일 마감가:
$2.30
열려 있는:
$2.31
하루 거래량:
3.21M
Relative Volume:
4.33
시가총액:
$320.93M
수익:
$79,600
순이익/손실:
$-48.26M
주가수익비율:
-4.6729
EPS:
-0.4922
순현금흐름:
$-28.24M
1주 성능:
-1.71%
1개월 성능:
-4.17%
6개월 성능:
+25.68%
1년 성능:
+49.35%
1일 변동 폭
Value
$2.28
$2.345
1주일 범위
Value
$2.2525
$2.425
52주 변동 폭
Value
$1.33
$2.61

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Name
명칭
Inhibikase Therapeutics Inc
Name
전화
(302) 295-3800
Name
주소
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Name
직원
35
Name
트위터
Name
다음 수익 날짜
2026-08-13
Name
최신 SEC 제출 서류
Name
IKT's Discussions on Twitter

Compare IKT vs VRTX, REGN, ARGX, MRNA, RVMD

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
IKT icon
IKT
Inhibikase Therapeutics Inc
2.30 326.51M 79,600 -48.26M -28.24M -0.4922
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
508.34 130.64B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
784.85 80.46B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
990.32 61.58B 4.16B 1.29B 734.26M 19.58
MRNA icon
MRNA
Moderna Inc
154.04 57.48B 2.23B -3.19B -1.60B -8.1462
RVMD icon
RVMD
Revolution Medicines Inc
190.95 43.68B 742.00K -1.37B -1.07B -7.0731

Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2026-03-04 개시 Ladenburg Thalmann Buy
2026-01-21 개시 BofA Securities Buy
2025-12-26 개시 H.C. Wainwright Buy
2025-12-11 개시 Cantor Fitzgerald Overweight
2025-02-12 다운그레이드 H.C. Wainwright Buy → Neutral

Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스

pulisher
Sep 08, 2026

Inhibikase advances IKT-001 in pivotal PAH Phase 3 - TipRanks

Sep 08, 2026
pulisher
Sep 08, 2026

Inhibikase updates corporate presentation, highlights Phase 3 IKT-001 program and timelines - TradingView

Sep 08, 2026
pulisher
Sep 08, 2026

Inhibikase (NASDAQ: IKT) tests PAH pill in pivotal global trial - Stock Titan

Sep 08, 2026
pulisher
Sep 04, 2026

IKT News | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill

Sep 04, 2026
pulisher
Sep 03, 2026

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Sep 03, 2026
pulisher
Sep 01, 2026

Inhibikase Therapeutics (IKT) Advances 3% as Shares Test Key Resistance ZoneMFI Overbought - dars.gov.et

Sep 01, 2026
pulisher
Sep 01, 2026

Inhibikase Therapeutics (NASDAQ:IKT) Stock Price Down 4.1%What's Next? - MarketBeat

Sep 01, 2026
pulisher
Aug 26, 2026

Inhibikase Therapeutics Appoints Deloitte & Touche LLP After Dismissing CohnReznick LLP as Auditor - Kalkine Media

Aug 26, 2026
pulisher
Aug 21, 2026

Inhibikase (IKT) Chart: Adds 1.70% to Close at $2.39 in Latest Trading; Trading Range: the Supplied Trading Band Runs From $2.27 to $2.51 for the Current SessionFibonacci Extension - siam.in

Aug 21, 2026
pulisher
Aug 19, 2026

Inhibikase (IKT) Q1 2026 Results: EPS Prints Above Forecast; Post-Earnings: Shares Finish 0.42% Higher at the CloseFree Cash Flow Trends - vinanet.vn

Aug 19, 2026
pulisher
Aug 18, 2026

Inhibikase Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 18, 2026
pulisher
Aug 18, 2026

Inhibikase Loss Widens as Phase 3 PAH Trial Expands - MyChesCo

Aug 18, 2026
pulisher
Aug 17, 2026

Inhibikase Therapeutics (IKT) Slips 1.5% as Shares Test Support at $2.25Shakeout Pattern - vinanet.vn

Aug 17, 2026
pulisher
Aug 16, 2026

Inhibikase Therapeutics (IKT) Holds Steady at $2.41 as Shares Consolidate Between $2.29 Support and $2.53 ResistanceReversal Setup Alerts - vinanet.vn

Aug 16, 2026
pulisher
Aug 16, 2026

IKT Q1 2026 Earnings: Narrower Loss of $0.10 Per Share Beats Estimates as Pre-Revenue Biotech Holds SteadyEPS Surprise History - vinanet.vn

Aug 16, 2026
pulisher
Aug 14, 2026

Perceptive group (IKT) discloses 6.9% Inhibikase stake through 10.3M warrant shares - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Nantahala reports 4.30% Inhibikase (IKT) stake across 5.81M shares - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 14, 2026
pulisher
Aug 14, 2026

IKT Q1 2026 Earnings: Narrower-than-Expected Loss Despite Modest Share PullbackNegative Surprise Momentum - vinanet.vn

Aug 14, 2026
pulisher
Aug 13, 2026

Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants - Stock Titan

Aug 13, 2026
pulisher
Aug 13, 2026

Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 13, 2026
pulisher
Aug 13, 2026

Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth - TipRanks

Aug 13, 2026
pulisher
Aug 12, 2026

Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026
pulisher
Aug 12, 2026

Inhibikase Q2 EPS of $(0.11) meets analyst consensus estimates - scanx.trade

Aug 12, 2026
pulisher
Aug 11, 2026

Is Inhibikase Therapeutics Inc (IKT) Positioned for Growth After Reporting $0.11 Loss? GF Score: 36/100 - GuruFocus

Aug 11, 2026
pulisher
Aug 11, 2026

LifeSci Capital Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 11, 2026
pulisher
Aug 11, 2026

Inhibikase grants $2.03 stock options to seven new hires - scanx.trade

Aug 11, 2026
pulisher
Aug 11, 2026

Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 11, 2026
pulisher
Aug 11, 2026

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - Yahoo Finance

Aug 11, 2026
pulisher
Aug 11, 2026

Inhibikase Therapeutics (IKT) Earnings Date and Reports 2026 $IKT - MarketBeat

Aug 11, 2026
pulisher
Aug 10, 2026

Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a shareEarnings Preview - TradingView

Aug 10, 2026
pulisher
Aug 09, 2026

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Aug 09, 2026
pulisher
Aug 02, 2026

Perceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT - MarketBeat

Aug 02, 2026
pulisher
Aug 01, 2026

Inhibikase Therapeutics (IKT) Declines 4.4% as Stock Pressures Key $2.07 Support ZoneBreadth Thrust - dars.gov.et

Aug 01, 2026
pulisher
Aug 01, 2026

Inhibikase Therapeutics (IKT) Slides 4.4% to $2.18 as Biotech Stock Presses Toward Key SupportEarly Entry Signals - vinanet.vn

Aug 01, 2026
pulisher
Jul 31, 2026

Inhibikase Therapeutics, Inc. Revenue Breakdown – NASDAQ:IKT - TradingView

Jul 31, 2026
pulisher
Jul 31, 2026

Inhibikase Wins FDA Orphan Status for PAH Drug Candidate - MyChesCo

Jul 31, 2026
pulisher
Jul 31, 2026

18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT) - Stock Titan

Jul 31, 2026
pulisher
Jul 31, 2026

H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status - Investing.com Canada

Jul 31, 2026
pulisher
Jul 29, 2026

Inhibikase Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Continues - dars.gov.et

Jul 29, 2026
pulisher
Jul 29, 2026

IKT Q1 2026 Earnings: Narrower-than-Expected Loss per Share; Shares Slide 4.3%Profit Cycle Analysis - vinanet.vn

Jul 29, 2026
pulisher
Jul 28, 2026

Inhibikase Therapeutics (IKT) Slips 1% as Shares Test Key Support at $2.21AI Trade Signals - vinanet.vn

Jul 28, 2026
pulisher
Jul 27, 2026

Inhibikase Therapeutics Inc (IKT) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Inhibikase Therapeutics Inc (IKT) Cash Flow - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Inhibikase Therapeutics Inc (IKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Inhibikase Therapeutics, Inc. $IKT Position Boosted by Kalehua Capital Management LLC - MarketBeat

Jul 27, 2026
pulisher
Jul 27, 2026

Inhibikase Therapeutics, Inc. Revenue Breakdown – BOATS:IKT - TradingView

Jul 27, 2026
pulisher
Jul 26, 2026

IKT|Inhibikase Therapeutics Inc|Price:2.330| - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

TradingKey - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

IKT|Inhibikase Therapeutics Inc|Price:2.355|Chg%:+0.025 - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

Inhibikase Therapeutics Inc (IKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 26, 2026

Inhibikase Therapeutics Inc (IKT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Inhibikase Therapeutics Inc 주식 (IKT) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Sands Capital Life Sciences Pu
10% Owner
Nov 21 '25
Buy
1.45
2,068,965
2,999,999
13,018,965
$58.41
price down icon 0.88%
$120.00
price down icon 3.21%
$39.77
price down icon 0.53%
$239.56
price down icon 2.42%
ONC ONC
$350.84
price down icon 0.74%
$190.95
price down icon 3.04%
자본화:     |  볼륨(24시간):